Stock listing
NASDAQ:FLNA Filana Therapeutics, Inc. Stock
Home listing (NASDAQ) of Filana Therapeutics, Inc.
Follow Filana Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:FLNA
$0.641 USD +0.096 (+17.7%)
Close on Nov 20, 2026
- Day range
- $0.590 – $0.653 USDNov 20, 2026
- Volume
- 1.32M sharesNov 20, 2026
- Market cap
- $30.98M USDAt the close on Nov 20, 2026 · price × 48.31M shares outstanding
- 52-week range
- $0.390 – $3.450 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.95M USDMedian day 336,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FLNA · Home | $0.641 USD | +0.096 (+17.7%) | 1,320,665 | $0.590 | $0.653 | $0.590 | $0.545 | Close on Nov 20, 2026 |
| Frankfurt:PX91 | €0.498 EUR | -0.004 (-0.7%) | — | €0.498 | €0.498 | €0.498 | €0.501 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FLNA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.641 | +0.096 | +17.7% | $0.590 | $0.653 | $0.590 | 1,320,665 | |
| $0.545 | +0.064 | +13.3% | $0.477 | $0.551 | $0.469 | 789,294 | |
| $0.481 | +0.011 | +2.3% | $0.465 | $0.495 | $0.465 | 542,599 | |
| $0.470 | +0.045 | +10.6% | $0.421 | $0.484 | $0.390 | 1,271,311 | |
| $0.425 | -0.023 | -5.1% | $0.460 | $0.470 | $0.423 | 315,512 | |
| $0.448 | -0.034 | -7.1% | $0.480 | $0.480 | $0.436 | 428,051 | |
| $0.482 | 0.000 | 0.0% | $0.500 | $0.510 | $0.480 | 213,816 | |
| $0.482 | -0.010 | -2.0% | $0.500 | $0.512 | $0.476 | 221,294 | |
| $0.492 | +0.040 | +8.7% | $0.461 | $0.505 | $0.460 | 556,382 | |
| $0.453 | +0.002 | +0.4% | $0.460 | $0.470 | $0.426 | 605,611 | |
| $0.451 | -0.121 | -21.2% | $0.570 | $0.583 | $0.450 | 1,258,838 | |
| $0.572 | -0.022 | -3.8% | $0.578 | $0.596 | $0.556 | 461,979 | |
| $0.594 | +0.033 | +5.9% | $0.572 | $0.600 | $0.560 | 361,033 | |
| $0.561 | -0.061 | -9.8% | $0.630 | $0.630 | $0.560 | 544,958 | |
| $0.622 | -0.038 | -5.8% | $0.659 | $0.659 | $0.620 | 214,783 | |
| $0.660 | +0.010 | +1.5% | $0.660 | $0.680 | $0.650 | 264,400 | |
| $0.650 | 0.000 | 0.0% | $0.660 | $0.660 | $0.630 | 347,000 | |
| $0.650 | +0.040 | +6.6% | $0.620 | $0.650 | $0.610 | 295,500 | |
| $0.610 | -0.030 | -4.7% | $0.630 | $0.640 | $0.600 | 297,000 | |
| $0.640 | -0.010 | -1.5% | $0.640 | $0.650 | $0.620 | 311,100 | |
| $0.650 | -0.010 | -1.5% | $0.660 | $0.670 | $0.640 | 250,100 | |
| $0.660 | -0.030 | -4.3% | $0.690 | $0.710 | $0.650 | 305,800 | |
| $0.690 | +0.010 | +1.5% | $0.670 | $0.700 | $0.670 | 198,400 | |
| $0.680 | -0.020 | -2.9% | $0.710 | $0.710 | $0.680 | 256,700 | |
| $0.700 | -0.060 | -7.9% | $0.750 | $0.760 | $0.700 | 327,900 | |
| $0.760 | +0.030 | +4.1% | $0.710 | $0.770 | $0.700 | 248,500 | |
| $0.730 | -0.010 | -1.4% | $0.730 | $0.740 | $0.720 | 253,200 | |
| $0.740 | -0.030 | -3.9% | $0.760 | $0.770 | $0.740 | 323,500 | |
| $0.770 | -0.050 | -6.1% | $0.810 | $0.810 | $0.760 | 360,400 | |
| $0.820 | +0.010 | +1.2% | $0.820 | $0.840 | $0.800 | 407,900 | |
| $0.810 | -0.010 | -1.2% | $0.800 | $0.820 | $0.780 | 610,800 | |
| $0.820 | -0.050 | -5.7% | $0.850 | $0.850 | $0.790 | 759,200 | |
| $0.870 | 0.000 | 0.0% | $0.890 | $0.900 | $0.830 | 670,000 | |
| $0.870 | -0.060 | -6.5% | $0.920 | $0.930 | $0.870 | 1,034,800 | |
| $0.930 | -0.040 | -4.1% | $0.970 | $1.040 | $0.930 | 1,691,200 | |
| $0.970 | +0.080 | +9.0% | $1.000 | $1.030 | $0.930 | 2,804,700 | |
| $0.890 | -0.030 | -3.3% | $0.930 | $0.950 | $0.860 | 769,500 | |
| $0.920 | +0.070 | +8.2% | $0.850 | $0.940 | $0.830 | 1,202,500 | |
| $0.850 | +0.100 | +13.3% | $0.730 | $0.890 | $0.720 | 2,053,900 | |
| $0.750 | -0.020 | -2.6% | $0.780 | $0.780 | $0.740 | 771,900 | |
| $0.770 | -0.100 | -11.5% | $0.850 | $0.900 | $0.740 | 2,313,600 | |
| $0.870 | -0.160 | -15.5% | $1.000 | $1.000 | $0.800 | 5,466,900 | |
| $1.030 | +0.290 | +39.2% | $0.980 | $1.300 | $0.900 | 94,301,500 | |
| $0.740 | +0.010 | +1.4% | $0.740 | $0.770 | $0.730 | 336,500 | |
| $0.730 | +0.010 | +1.4% | $0.720 | $0.730 | $0.710 | 122,800 | |
| $0.720 | +0.040 | +5.9% | $0.690 | $0.720 | $0.680 | 274,500 | |
| $0.680 | -0.020 | -2.9% | $0.690 | $0.700 | $0.670 | 379,600 | |
| $0.700 | -0.020 | -2.8% | $0.730 | $0.730 | $0.680 | 446,000 | |
| $0.720 | -0.050 | -6.5% | $0.770 | $0.770 | $0.710 | 379,300 | |
| $0.770 | -0.040 | -4.9% | $0.810 | $0.810 | $0.770 | 309,600 | |
| $0.810 | 0.000 | 0.0% | $0.800 | $0.810 | $0.770 | 303,300 | |
| $0.810 | +0.010 | +1.3% | $0.790 | $0.810 | $0.760 | 271,300 | |
| $0.800 | -0.020 | -2.4% | $0.810 | $0.820 | $0.750 | 509,500 | |
| $0.820 | -0.010 | -1.2% | $0.820 | $0.850 | $0.800 | 285,400 | |
| $0.830 | -0.030 | -3.5% | $0.890 | $0.890 | $0.820 | 273,200 | |
| $0.860 | 0.000 | 0.0% | $0.900 | $0.900 | $0.820 | 347,200 | |
| $0.860 | -0.040 | -4.4% | $0.900 | $0.900 | $0.850 | 217,000 | |
| $0.900 | -0.030 | -3.2% | $0.920 | $0.930 | $0.880 | 139,700 | |
| $0.930 | +0.010 | +1.1% | $0.930 | $0.930 | $0.910 | 169,900 | |
| $0.920 | 0.000 | 0.0% | $0.910 | $0.940 | $0.910 | 110,300 | |
| $0.920 | -0.029 | -3.0% | $0.940 | $0.940 | $0.920 | 56,800 | |
| $0.949 | +0.019 | +2.0% | $0.919 | $0.957 | $0.913 | 110,136 | |
| $0.930 | -0.030 | -3.1% | $0.950 | $0.951 | $0.920 | 121,940 | |
| $0.960 | +0.020 | +2.1% | $0.950 | $0.960 | $0.940 | 106,200 | |
| $0.940 | -0.030 | -3.1% | $0.950 | $0.980 | $0.910 | 167,700 |
Splits
1 split · NASDAQ:FLNA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-7 | Consolidation |
- Ticker
- NASDAQ:FLNA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Latest news
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
Nov 11, 2026
Closed $0.482 (0.0%) on Nov 11, 2026
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
Nov 5, 2026
Closed $0.451 (-21.2%) on Nov 5, 2026
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Oct 28, 2026
Closed $0.65 (0.0%) on Oct 28, 2026
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Sep 22, 2026
Closed $1.03 (+39.2%) on Sep 22, 2026
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Jul 29, 2026
Closed $0.87 (-1.1%) on Jul 29, 2026
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
May 7, 2026
Closed $1.36 (-5.6%) on May 7, 2026
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
May 5, 2026
Closed $1.38 (-1.4%) on May 5, 2026
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Apr 15, 2026
Closed $1.61 (+1.3%) on Apr 15, 2026
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Mar 12, 2026
Closed $1.95 (-6.7%) on Mar 12, 2026
Filana Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 9 in all · newest Nov 11, 2026 · oldest 2026
Where Filana Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FLNA · Home listing · This page | NASDAQ | United States | USD |
| gettex:PX91 | gettex | Germany | EUR |
| LS Exchange:A2PGL8 | LS Exchange | Germany | EUR |
| BOATS:FLNA | BOATS | United States | USD |
| Lang & Schwarz:A2PGL8 | Lang & Schwarz | Germany | EUR |
| Tradegate:PX91 | Tradegate | Germany | EUR |
| BMV:FLNA | BMV | Mexico | MXN |
| Frankfurt:PX91 | Frankfurt | Germany | EUR |
| Dusseldorf:PX91 | Dusseldorf | Germany | EUR |
| Hamburg:PX91 | Hamburg | Germany | EUR |
| Munich:PX91 | Munich | Germany | EUR |
| Stuttgart:PX91 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.5× against a median of 3.3×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$16.01M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.25
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Filana Therapeutics, Inc. · NASDAQ:FLNA | US$30.98M | −US$16.01M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.25 |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.52M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Enimmune Corporation · TPEX:6564 | US$31.74M | US$26.87M | n/a | 18.4× | n/a | 10.4× | −341.0% | 0.3× | n/a |
| Molecure SA · GPW:MOC | US$31.66M | US$29.60M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.03M | US$27.78M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.03M | US$19.80M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Caribou Biosciences, Inc. · NASDAQ:CRBU | US$30.71M | −US$37.75M | n/a | −4.0× | n/a | 0.4× | n/a | 0.3× | 1.87 |
| Avecho Biotechnology Limited · ASX:AVE | US$30.69M | US$26.46M | n/a | 32.3× | n/a | 24.3× | −356.8% | 0.1× | n/a |
| Kalaris Therapeutics, Inc. · NASDAQ:KLRS | US$30.47M | −US$51.05M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.47 |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| Median of the others | US$30.87M | US$26.67M | 15.4× | 3.3× | −356.8% | 0.0× | 1.71 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.86 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Richard J. Barry | President & Chief Executive Officer |
| Eric Schoen | Chief Financial Officer |
| R. Christopher Cook | Chief Operating and Legal Officer |
| Angélique Bordey | SVP, Neuroscience |
| George Thornton | Sr. VP, Technology |
| Jack Moore | Sr. VP, Clinical Development |
| Michael Zamloot | Sr. VP, Tech. Operations |
| Joseph Hulihan | Chief Medical Officer |
| Nancy Teasdale | Head of Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Claude Nicaise | Independent Director, Chairman of the Board |
| Dawn Carter Bir | Independent Director |
| Jill M. Quigley | Director |
| Patrick Scannon MD | Independent Director |
| Pierre Gravier | Independent Director |
| Richard J. Barry | President & Chief Executive Officer |
| Robert Anderson | Independent Director |
Events
- Next results
- Mar 11, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −21.1% |
| Q2 2026 | Jul 29, 2026 · Before open | −1.1% |
| Q1 2026 | May 7, 2026 · Before open | −5.6% |
| Q4 2025 | Mar 12, 2026 | −4.8% |
| Q3 2025 | Nov 12, 2025 · Before open | +4.8% |
| Q2 2025 | Aug 14, 2025 | +2.6% |
| Q1 2025 | May 8, 2025 | +13.5% |
| Q4 2024 | Mar 3, 2025 · Before open | +3.3% |
| Q3 2024 | Nov 7, 2024 · Before open | −4.6% |
| Q2 2024 | Aug 8, 2024 · Before open | −13.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 | +15.3% |
| Q4 2023 | Feb 28, 2024 · Before open | −0.3% |
| Q3 2023 | Nov 7, 2023 · Before open | +4.3% |
| Q2 2023 | Aug 3, 2023 · Before open | −0.7% |
| Q1 2023 | May 1, 2023 · Before open | +0.5% |
| Q4 2022 | Feb 28, 2023 | +1.0% |
| Q3 2022 | Nov 7, 2022 · Before open | −3.3% |
| Q2 2022 | Aug 4, 2022 · After close | +2.0% |
| Q1 2022 | May 5, 2022 · Before open | −1.7% |
| Q4 2021 | Mar 1, 2022 | −4.5% |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||||||
| Cost of revenue | 936.0K | 22.0K | 58.0K | 69.0K | 68.0K | 58.0K | ||||
| Gross profit | -936.0K | -22.0K | -58.0K | -69.0K | -68.0K | -58.0K | ||||
| Research and development | 26.6M | 69.6M | 89.4M | 68.0M | 24.8M | 7.29M | 6.30M | 2.97M | 7.62M | 9.18M |
| Selling, general and administrative | 68.8M | 71.8M | 16.5M | 12.0M | 8.05M | |||||
| Operating income | -95.4M | -141.4M | -106.0M | -80.0M | -32.9M | -6.45M | -4.96M | -6.66M | -11.9M | -15.0M |
| Depreciation and amortization | 903.0K | 952.0K | 1.08M | 804.0K | 310.0K | 22.0K | 58.0K | 69.0K | 68.0K | 58.0K |
| EBITDA | -94.5M | -140.5M | -104.9M | -79.2M | -32.6M | -6.42M | -4.90M | -6.59M | -11.9M | -14.9M |
| Income before tax | -91.0M | -24.3M | -97.2M | -76.2M | -32.4M | -6.33M | -4.63M | -6.56M | -11.9M | -14.8M |
| Income tax | 0 | 0 | ||||||||
| Net income | -91.0M | -24.3M | -97.2M | -76.2M | -32.4M | -6.33M | -4.63M | -6.56M | -11.9M | -14.8M |
| Earnings per share, basic | -1.88 | -0.53 | -2.32 | -1.90 | -0.82 | -0.24 | -0.27 | -0.61 | -1.82 | -2.28 |
| Earnings per share, diluted | -1.88 | -1.46 | -2.32 | -1.90 | -0.82 | -0.24 | -0.27 | -0.61 | -1.82 | -2.28 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 95.5M | 128.6M | 121.1M | 201.0M | 233.4M | 93.5M | 23.1M | 19.8M | 10.5M | 16.6M |
| Short-term investments | 2.10M | |||||||||
| Receivables | 120.0K | 947.0K | 962.0K | |||||||
| Current assets | 97.7M | 136.5M | 129.6M | 211.2M | 244.5M | 94.0M | 23.3M | 20.0M | 10.7M | 19.1M |
| Property, plant and equipment | 20.6M | 21.0M | 21.9M | 22.9M | 20.6M | 11.0K | 47.0K | 87.0K | 156.0K | 232.0K |
| Total assets | 118.4M | 157.5M | 151.7M | 234.8M | 266.8M | 94.3M | 23.5M | 20.1M | 10.8M | 19.3M |
| Accounts payable | 6.40M | 7.65M | 10.6M | 4.02M | 7.13M | 911.0K | 453.0K | 294.0K | 424.0K | 303.0K |
| Current liabilities | 43.8M | 11.8M | 14.2M | 7.06M | 12.5M | 1.86M | 1.39M | 511.0K | 1.13M | 665.0K |
| Total debt | 139.0K | 236.0K | 293.0K | 90.0K | ||||||
| Total liabilities | 44.0M | 11.8M | 14.2M | 7.29M | 12.9M | 2.10M | 1.39M | 511.0K | 1.13M | 665.0K |
| Shareholders' equity | 74.4M | 145.7M | 137.5M | 227.5M | 253.9M | 92.2M | 22.1M | 19.6M | 9.70M | 18.6M |
| Shares outstanding | 48.3M | 48.2M | 42.2M | 41.7M | 40.0M | 35.2M | 21.8M | 17.2M | 6.60M | 6.59M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -32.3M | -116.9M | -82.0M | -77.5M | -30.2M | -5.38M | -2.51M | -4.77M | -8.24M | -12.2M |
| Capital spending | -581.0K | -103.0K | -414.0K | -2.71M | -22.2M | 0 | -18.0K | 0 | 0 | -75.0K |
| Free cash flow | -32.8M | -117.0M | -82.4M | -80.2M | -52.4M | -5.38M | -2.53M | -4.77M | -8.24M | -12.3M |
| Cash from investing | -581.0K | -103.0K | -414.0K | -2.71M | -22.2M | 360.0K | -18.0K | 2.10M | -2.17M | |
| Cash from financing | -239.0K | 124.5M | 2.56M | 47.8M | 192.3M | 75.4M | 5.81M | 14.1M | -284.0K | |
| Share buybacks | -60.0K | |||||||||
| Change in cash | -33.1M | 7.44M | -79.9M | -32.4M | 139.9M | 70.4M | 3.27M | 9.33M | -6.14M | -14.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| 8-K · Current report | Sep 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jul 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 8-K · Current report | Jun 15, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Feb 19, 2026 | Current report | SEC |
| 8-K · Current report | Dec 23, 2025 | Material contract | SEC |
| 8-K/A · Current report, amended | Dec 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 8-K · Current report | Dec 17, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 8, 2025 | Other filings | SEC |
| 424B2 · Prospectus | Dec 5, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 3, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 21, 2025 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 8-K · Current report | Mar 11, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| 8-K · Current report | Feb 27, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 7, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 29, 2024 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 26, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 20, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 8-K/A · Current report, amended | Oct 1, 2024 | Management or board change | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| 8-K · Current report | Sep 17, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2024 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 21, 2024 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 22, 2024 | Current report | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| 8-K · Current report | Jul 17, 2024 | Management or board change | SEC |
| 8-K · Current report | Jul 1, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 8-K · Current report | May 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 25-NSE | May 3, 2024 | Other filings | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Mar 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 22, 2024 | Annual report | SEC |
| 10-K · Annual report | Feb 28, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| CERT · Exchange's certificate of listing | Jan 3, 2024 | Other filings | SEC |
| 424B2 · Prospectus | Jan 3, 2024 | Offer document | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 3, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 3, 2024 | Material contract | SEC |
| 8-A12G · Registration of a class of shares | Jan 2, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 12, 2023 | Current report | SEC |
| 8-K · Current report | Dec 11, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 7, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 13, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 14, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 10, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| UPLOAD · Letter from the SEC | Jul 28, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 5, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2023 | Insider trade | SEC |
| 8-K · Current report | May 8, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 2, 2023 | Insider trade | SEC |
| 8-K · Current report | May 1, 2023 | Material contract | SEC |
| 424B5 · Prospectus | May 1, 2023 | Offer document | SEC |
| S-3ASR · Registration statement | May 1, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 1, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2023 | Results | SEC |
| DEF 14A · Proxy statement | Mar 27, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 16, 2023 | Management or board change | SEC |
| ARS · Annual report to shareholders | Mar 16, 2023 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 16, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 4 · Change in ownership | Mar 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2023 | Insider trade | SEC |
| 10-K · Annual report | Feb 28, 2023 | Annual report | SEC |
| 8-K · Current report | Feb 28, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2023 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 7, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 24, 2023 | Current report | SEC |
| 5 · Annual statement of ownership | Jan 3, 2023 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Filana Therapeutics, Inc.’s releases
- Common shares
- 48,307,896
- Fully diluted
- 48,307,896
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 48,307,896 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 48,307,896 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Saira Ramasastry Other companies: Sensei Biotherapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jun 15, 2026); Mirum Pharmaceuticals, Inc. (Director · Since at least Jun 2, 2022); Day One Biopharmaceuticals Inc (Director · Since at least May 26, 2021); Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Repros Therapeutics (Director · Mar 25, 2013 – Jan 29, 2018 · Past); Sangamo Therapeutics, Inc. (Director · Jun 21, 2012 – Feb 25, 2022 · Past) | Director · Feb 11, 2013 – Dec 13, 2019 · Past |
| Peter S Roddy Other companies: Cytokinetics, Incorporated (SVP Finance & CAO · Feb 8, 2018 – Feb 27, 2018 · Past); Aspira Women's Health Inc. (Director · Feb 18, 2010 – Mar 17, 2016 · Past) | Chief Financial Officer · May 1, 2010 – Apr 8, 2016 · Past |
| Claude Nicaise Other companies: Sarepta Therapeutics, Inc. (Director · Since at least Jun 5, 2026) | Independent Director, Chairman of the Board · Since at least Nov 5, 2026 |
| Pierre Gravier Other companies: PTC Therapeutics, Inc. (Chief Financial Officer · Since at least Jul 13, 2023) | Independent Director · Since at least Dec 6, 2023 |
| Richard J. Barry Other companies: Sarepta Therapeutics, Inc. (Director · Since at least Dec 31, 2020) | President & Chief Executive Officer · Since at least Jun 11, 2021 |
| Angélique Bordey | SVP, Neuroscience · Since at least Oct 28, 2026 |
| Dawn Carter Bir | Independent Director · Since at least Nov 5, 2026 |
| Eric Schoen | Chief Financial Officer · Since at least Oct 28, 2026 |
| Freda Nassif | Chief Business Officer · Nov 18, 2024 – Apr 17, 2025 · Past |
| George Thornton | Sr. VP, Technology · Since at least Nov 5, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Jack Moore | Sr. VP, Clinical Development · Since at least Nov 4, 2026 |
| James William Kupiec | Chief Medical Officer · Oct 3, 2023 – Nov 29, 2024 · Past |
| Jaren Landen | Chief Clinical Dev. Officer · Nov 18, 2024 – Nov 18, 2024 · Past |
| Jill M. Quigley | Director · Since at least Nov 11, 2026 |
| Joseph Hulihan | Chief Medical Officer · Since at least Nov 5, 2026 |
| Michael Zamloot | Sr. VP, Tech. Operations · Since at least Nov 5, 2026 |
| Nadav Friedmann | Chief Medical Officer, Director · May 27, 2022 – Dec 31, 2022 · Past |
| Nancy Teasdale | Head of Regulatory Affairs · Since at least Nov 5, 2026 |
| Patrick J Md Phd Scannon | Director · Since at least May 4, 2023 |
| Patrick Scannon MD | Independent Director · Since at least Nov 4, 2026 |
| R. Christopher Cook | Chief Operating and Legal Officer · Since at least Nov 5, 2026 |
| Robert Anderson | Independent Director · Since at least Nov 5, 2026 |
| Robert Christopher Cook | Chief Operating & Legal Office · Since at least Oct 28, 2022 |
| Robert Eugene Anderson Jr | Director · Since at least May 23, 2025 |
| Robert Z Gussin | Director · Since at least May 25, 2006 |
Log in to ask 6ix AI your own questions about Filana Therapeutics, Inc.